Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop.
about
A Pathophysiologic Approach to Biomarkers in Acute Respiratory Distress SyndromeGlobal histone post-translational modifications and cancer: Biomarkers for diagnosis, prognosis and treatment?Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical TrialsIn vitro models of cancer stem cells and clinical applicationsRemoving obstacles in neuroscience drug discovery: the future path for animal models.Center-Within-Trial Versus Trial-Level Evaluation of Surrogate EndpointsPre-Osteoarthritis: Definition and Diagnosis of an Elusive Clinical EntityNanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases.Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challengeValidity and reliability of electroencephalographic frontal alpha asymmetry and frontal midline theta as biomarkers for depression.Resting-state functional connectivity and nicotine addiction: prospects for biomarker developmentA comprehensive approach toward novel serum biomarkers for benign prostatic hyperplasia: the MPSA Consortium.Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy--a single centre, open-label study.Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model.Blood-based biomarkers of Alzheimer's disease: challenging but feasibleEvaluating the Proportion of Treatment Effect Explained by a Continuous Surrogate Marker in Logistic or Probit Regression Models.Biomarkers for anti-angiogenic therapy in cancer.Towards a combined prognostic index for survival in HIV infection: the role of 'non-HIV' biomarkersCalprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritisDo dopamine agonists or levodopa modify Parkinson's disease progression?A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables.Identifying biomarkers as diagnostic tools in kidney transplantationDrug discovery and mental illnessCDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.Novel outcomes and end points: biomarkers in chronic obstructive pulmonary disease clinical trialsNeuroimaging and biomarkers in addiction treatment.A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials.Synovial Tissue Response to Treatment with TNF Blockers in Peripheral SpondyloarthritisThe role of surrogate markers in the clinical development of antiretroviral therapy: a model for early evaluation of targeted cancer drugs.Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy.Biomarkers for kidney involvement in pediatric lupus.Drug development in pediatric psychiatry: current status, future trends.Development and use of biomarkers in oncology drug development.Correlates of protection for rotavirus vaccines: Possible alternative trial endpoints, opportunities, and challenges.Quantitative differences in HTLV-I antibody responses: classification and relative risk assessment for asymptomatic carriers and ATL and HAM/TSP patients from JamaicaBiomarkers in acute lung injury.Evidence from biomarkers and surrogate endpoints.Generating Virtual Patients by Multivariate and Discrete Re-Sampling TechniquesInclusion of biomarkers for detecting perturbations in the heart and lung and lipid/carbohydrate metabolism in National Toxicology Program studies.Clinical research in primary stroke prevention: needs, opportunities, and challenges.
P2860
Q26765351-4A669ED5-A625-41B6-ABF8-7E196C54E1B7Q26775413-22DD504E-CEBA-43BE-BD02-1C54246B72F7Q26796253-60CD2336-AFBC-42AE-8EDB-AB88CC3CD061Q28076101-49193997-B867-4D6C-A69E-AF61147F90DBQ28755229-AC72B593-EF2A-4EA2-B8E0-7B9AB078329FQ30370596-D5D4D7EC-3711-429E-9AEB-755F1288A13BQ30380084-9BBABE14-B076-4591-AF03-4695C1710B33Q30387307-73141DD6-143C-4B54-A8C0-412F7BFB8935Q30540217-8D9600AE-C4C4-446B-8AAC-DE90FD143FA6Q30558549-A7106783-5977-4B2B-89CA-A315DE555D55Q30992161-6F541119-E000-4C21-8BCC-FA3F8B982BB9Q33320106-1CA3C578-1DA0-42E4-9617-614478930B38Q33390403-65D9EB45-AB0C-4FCE-A6EF-B80183CE3FD1Q33538308-10F87540-FA55-4883-A2C8-DED090709B1CQ33824444-75F3B5CC-E5F6-4540-8A09-3969E6F5D9FBQ33932454-51EECDBC-E7DA-40B0-B86C-4FD5C9F216A9Q34695003-FC771E25-83FE-4CD3-B883-D9E6A1442953Q34802684-EB69953E-F837-4451-8CBD-9C28D9E66FC1Q34941693-F57D149A-18EA-42D6-8991-8CEABACC81A5Q35015794-08F68404-6B54-47F2-996D-21AD5436CA15Q35016789-1D5DD735-BEE3-4124-B848-466E576A52C4Q35049801-730E7CBD-39DE-40E0-8AD1-7ED0D752179CQ35236519-4FE9AD05-53C5-45F5-A0BD-63A8EA53BC2BQ35528462-05D77870-00F5-4645-A985-BDFF6E926688Q35532191-DE456502-3322-4BAE-B35E-AA8F5676BD45Q35594897-FA7AC4C4-ABA1-4825-B299-8802E1EBB8BCQ35681400-FAC18044-1817-482F-A06E-81E95496F9F4Q35687019-9287F293-046B-4AE6-8B50-F91686DD48E6Q35740281-FC2B3581-2674-4BBD-843E-9B8D10D28818Q35792872-A4D412F8-3BD1-4150-9A1C-0EBF653B3D1EQ35810911-24C03E38-4F72-4DFA-9BFB-86493D6CD59EQ35811894-9484DA20-B75D-4A7C-941F-E3A24B655718Q35812532-4000844B-38E6-44D1-88ED-42F088A846BEQ35886464-9D97895F-6BD2-4E3B-B713-07E17222D233Q35891629-0481F3E8-442D-4FDD-A109-2E888EA2FA10Q35958312-BD9E3B0D-38DD-481A-A152-3B76A058B8F2Q36045330-C46FD52E-BADF-4D3E-9E6B-F748136A0F74Q36080108-A6E7FE7E-A337-429D-98C2-71520D19876BQ36148595-D7EB3EF5-9D5F-4175-8B83-DAE5ED8562B4Q36163351-C4842A7C-55E1-428F-B9FC-8B85CCE89A34
P2860
Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Considerations in the evaluati ...... Institutes of Health workshop.
@ast
Considerations in the evaluati ...... Institutes of Health workshop.
@en
Considerations in the evaluati ...... Institutes of Health workshop.
@nl
type
label
Considerations in the evaluati ...... Institutes of Health workshop.
@ast
Considerations in the evaluati ...... Institutes of Health workshop.
@en
Considerations in the evaluati ...... Institutes of Health workshop.
@nl
prefLabel
Considerations in the evaluati ...... Institutes of Health workshop.
@ast
Considerations in the evaluati ...... Institutes of Health workshop.
@en
Considerations in the evaluati ...... Institutes of Health workshop.
@nl
P2093
P1476
Considerations in the evaluati ...... Institutes of Health workshop.
@en
P2093
De Gruttola VG
Downing GJ
Ellenberg SS
Friedman L
Prentice R
P304
P356
10.1016/S0197-2456(01)00153-2
P407
P577
2001-10-01T00:00:00Z